Jamerson KA. American Hypertension Society 20th Annual Scientific Session; May 14-18, 2005; San Francisco, CA.

VALUE: New-onset diabetes in an amlodipine-based vs valsartan-based therapy in high-risk hypertensives Diagnostic criteria Valsartan

n (%)Amlodipine n (%)

Odds ratio (95% CI)

p

Adverse event reports, new antidiabetic medication, and/or fasting glucose >7.0 mmol/L

580 (11.5) 718 (14.5) 0.77 (0.69-0.87)

<0.0001

New antidiabetic medication and/or fasting glucose >7.0 mmol/L

495 (9.8) 586 (11.8) 0.82 (0.72-0.93)

0.0015